logo-loader
viewRyah Medtech Inc

RYAH Medtech’s dose-measuring inhaler passes milestone safety test

The New York-based company said completing the safety test enabled RYAH to initiate global medical registration applications

Ryah Medtech Inc - RYAH Medtech’s dose-measuring inhaler passes milestone safety test
CEO Gregory Wagner said RYAH’s objective is to provide the most comfortable and secure experience for patients utilizing plant-based treatment options

RYAH Medtech Inc revealed Thursday that the company’s dose-measuring dry herb inhaler has passed key medical device compliance tests. 

In a statement, the privately-owned New York-based company said it cleared the CE-RED NB and IEC 60601 medical device safety tests, which constitute technical standards for the safety and performance of medical electrical equipment, published by the International Electrotechnical Commission. 

RYAH Medtech said it is a widely accepted benchmark and compliance with IEC60601 has become a requirement for the commercialization of electrical medical equipment in many countries. 

READ: RYAH Medtech data finds 78% of male medical cannabis patients use cannabis daily or near-daily, start treatment earlier in life

“RYAH’s distinct objective is to provide the most comfortable and secure experience for patients utilizing plant-based treatment options. The completion of the IEC 60601 device safety test directive marks a new milestone for RYAH and reconfirms our intention to architect the highest quality delivery solutions for plant-based medicine,” said RYAH Medtech CEO Gregory Wagner.

“As we continue to focus on transforming patient care with accurate data analytics and perfecting our safety model, countries around the world are quickly and permanently reshaping their understanding of plant-based medicine: they tend to only embrace the devices which meet and exceed stringent safety standards,” he added.

The RYAH Medtech boss noted that completing the safety test enabled the company to initiate global medical registration applications while RYAH continued to move forward towards its Canadian Securities Exchange listing.

Designed to give patients control, the RYAH inhaler measures inhalations to deliver precise and predictable results. It connects to a mobile app with features like stat-tracking and pre-sets for temperature and dosage that are customized to individual needs.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ryah Medtech Inc named herein, including the promotion by the Company of Ryah Medtech Inc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PotBotics says its platform will change how doctors treat patients with...

PotBotics Informatics Specialist Cayla Rosenblum tells Proactive Investors the data aggregation and technology company will soon unveil its new platform called Ryah MD, which works together with PotBotic's vaporizer called Ryah, allowing doctors to make recommendations to patients who use...

on 18/3/19

2 min read